前列腺癌精囊腺靶区超低分次放疗:基于HYPO-RT-PC分次方案的治疗计划研究
本研究基于HYPO-RT-PC分次方案,设计将精囊腺纳入靶区的超低分次同步推量放疗计划,并与常规分次比较剂量学指标。结果显示超低分次同步推量放疗对危及器官剂量更低,但选择性精囊腺D98%低7-12 Gy3;仅前列腺照射时精囊腺近端非计划剂量覆盖可能较高。
要点
- 基于HYPO-RT-PC方案可设计前列腺及精囊腺基底部的超低分次同步推量放疗计划。
- 与常规分次相比,超低分次同步推量放疗对直肠和膀胱的QUANTEC体积标准低2%-7%和2%-4%。
- 仅前列腺照射时精囊腺近端10 mm的非计划剂量覆盖可能较高。
核心结论
- 基于HYPO-RT-PC分次方案、采用同步推量技术对前列腺和精囊腺基底部进行超低分次放疗,相比常规分次可降低危及器官的EQD2剂量。
- 仅前列腺治疗时精囊腺近端的非计划剂量可能较高。
研究设计与样本
- 治疗计划研究,基于线性二次模型(α/β=2 Gy和3 Gy)从常规分次临床方案(选择性精囊腺50.0 Gy/25次,确认精囊腺侵犯70.0 Gy/35次)推导两种等效超低分次同步推量方案。
- 两种方案前列腺剂量均为42.7 Gy/7次,选择性精囊腺/确认精囊腺侵犯剂量分别为31.2 Gy/37.8 Gy(α/β=2 Gy)和32.7 Gy/40.1 Gy(α/β=3 Gy)。
- 优化近端10 mm和20 mm的容积旋转调强放疗计划,评估靶区和危及器官的剂量体积指标。
主要发现
- 超低分次同步推量放疗的剂量指标总体低于常规分次。
- 基于QUANTEC的体积标准,超低分次同步推量放疗中直肠低2%-7%,膀胱低2%-4%。
- 选择性精囊腺D98%在超低分次同步推量放疗中低7-12 Gy3,确认精囊腺侵犯相应数据低约2-3 Gy3。
- 仅前列腺治疗(42.7 Gy)时,精囊腺(10 mm)V90%(29.5 Gy)中位(IQR)为临床靶区99%(87-100)、计划靶区78%(58-99)。
关键数值与推荐
- 前列腺剂量42.7 Gy/7次。
- 选择性精囊腺剂量31.2 Gy(α/β=2 Gy)或32.7 Gy(α/β=3 Gy)。
- 确认精囊腺侵犯剂量37.8 Gy(α/β=2 Gy)或40.1 Gy(α/β=3 Gy)。
- 常规分次对照:选择性精囊腺50.0 Gy/25次,确认精囊腺侵犯70.0 Gy/35次。
- 精囊腺(10 mm)V90%(29.5 Gy):临床靶区中位99%(IQR 87-100),计划靶区中位78%(IQR 58-99)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Ultrahypofractionated (UHF) radiation therapy (RT) has become a treatment alternative for patients with localized prostate cancer. In more advanced cases, seminal vesicles (SVs) are routinely included in the target volume. The Scandinavian HYPO-RT-PC trial, which compared 42.7 Gy in 7 fractions (fr) to conventional fractionation (CF), did not include SVs in the clinical target volume. The primary objective of the present work was to implement a ultrahypofractionated-simultaneous integrated boost (UHF-SIB) for prostate cancer RT, incorporating SVs into the target volume based on this fractionation schedule. A secondary objective was to analyze the unintentional dose coverage of SVs from state-of-the-art volumetric modulated arc therapy treatments to the prostate gland only. METHODS AND MATERIALS: Two different equieffective UHF-SIB treatment schedules to SVs were derived based on the CF clinical schedule (50.0 Gy/25 fr to elective SVs and 70.0 Gy/35 fr to verified SV-invasion (SVI)) using the linear quadric model with α/β = 2 Gy and 3 Gy. The dose to the prostate was 42.7 Gy/7 fr in both schedules, with 31.2 Gy/37.8 Gy (α/β = 2 Gy) and 32.7 Gy/40.1 Gy (α/β = 3 Gy) to elective SV/verified SVI. Volumetric modulated arc therapy plans to the proximal 10 mm and 20 mm were optimized, and dose-volume metrics for target volumes and organs at risk were evaluated. RESULTS: Dose metrics were overall lower for UHF-SIB compared with CF. QUANTEC-based volume criteria were 2% to 7% lower for the rectum and 2% to 4% lower for the bladder in the UHF-SIB. The D98% to elective SV was 7 to 12 Gy3 lower with UHF-SIB, and the corresponding data for verified SVI were approximately 2 to 3 Gy3. The SV(10 mm) V90%/(29.5 Gy) for prostate-only treatments (42.7 Gy) were as follows: median (IQR), 99% (87-100) and 78% (58-99) for the clinical target volume and planning target volume, respectively. CONCLUSIONS: UHF RT based on the HYPO-RT-PC fractionation schedule, with a SIB technique, to the prostate and the base of the SV can be planned with lower doses (EQD2) to organs at risk, compared with CF. The unintentional dose to the proximal parts of SVs in prostate-only treatment can be substantial.
引用
- Wieslander E, Jóhannesson V, Nilsson P, et al. Ultrahypofractionated Radiation Therapy for Prostate Cancer Including Seminal Vesicles in the Target Volume: A Treatment-planning Study Based on the HYPO-RT-PC Fractionation Schedule. Adv Radiat Oncol. 2024. PMID: 38883997. doi:10.1016/j.adro.2024.101531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。